1. 1.Utilización y vehiculización de PPRHs contra dianas no medicables, LncRNAs, PCSK9 y como sensores de enfermedades infecciosas (Programa General del Conocimiento) 2022-2025


  1. 2.Diagnòstci i tractament de Sars-Cov-2 per formació de triplex (Fundació la Marató de TV3) 2021-2023


  1. 3.TERAPIA GENICA MEDIADA POR PPRHS: VEHICULIZACION, SILENCIAMIENTO, REPARACION Y APROXIMACIONES IN VIVO (RTI2018-093901-B-I00, 2019-2021)


  1. 4.PPRHs: Advanced design, Delivery, OMICs and therapeutical applications in lymphomas, Immunotherapy and Gene Repair (SAF-R, 2015-2018)


  1. 5.Biomedical Applications of PolyPurine Reverse Hoogsteen Hairpins: Gene

        silencing in cancer and Repair. (Biomedicine-SAF) 2012-2014


  1. 6.Nutrigenomic Approach to Study the Potential of Walnut Polyphenols and Their Human Metabolites in Cancer Prevention and Treatment. (California Walnut Comission) 2012-2014


  1. 7.Regulation of differentially expressed genes in cells resistant to Methotrexate: Control by miRNAs and Gene Therapy using Polypurine Hairpins. (Biomedicine-SAF) 2009-2011.

  2. 8.Differentially expressed Nodes in Genomic Networks from Methotrexate resistant cells and sensitization by siRNAs; DHFR: regulation by Sp3, Stability of the protein and Gene Therapy. (Biomedicine-SAF) 2006-2008

  3. 9.Collaborative project with Merck-Farma regarding knock-out of specific genes with pro-angiogenic function (2005)

  4. 10.Genomic profile of methotrexate resistance, molecular mechanisms of DHFR regulation and gene therapy. CICYT-SAF (2002-2005)

  5. 11.Collaborative project with Merck-Farma laboratories related with antiangiogenic targets (2004)

  6. 12.Fundació Caixa de Pensions 'La Caixa'; Functional and Molecular interaction of the glutamic and adenosine metabotropic receptors and their role in the Alzheimer disease. Identification of new targets for the diagnostic and therapy of the disease.  (2002-2005)

  7. 13.Collaborative project with Nutrexpa laboratories (2002-2003)

  8. 14.Cancer Chemotherapy: Resistance and Lipidic Metabolism. SGR (2002-2005)

  9. 15.Collaborative project with Merck-Farma laboratories related with proapoptotic targets (2001-2002)

  10. 16.Functional genomic study of the effect of statins and PPAR activators on the gene profile induced by oxidized LDL in THP-1 cells.  FISss (2001-2003)

  11. 17.Cancer Chemotherapy: Resistance and Lipidic Metabolism. SGR (2000-2002)

  12. 18.Targeting of genes and antisense oligonucleotides by novel liposome formulations: Evaluation of their therapeutic efficacy in human leukemia. JNIC (2000-2003)

  13. 19.Collaborative project with Merck-Farma laboratories (1999-2000)

  14. 20.Transcriptional and postranscriptional regulation of DHFR. Inhibition of the protein by oligonucleotides isolated from combinatorial libraries. CICYT-SAF (1999-2002)

  15. 21.Cancer Chemotherapy: Resistance and Lipidic Metabolism. SGR (1998)

  16. 22.Resistance to chemotherapy developed by methotrexate: Molecular mechanisms and modulators. CICYT-SAF (1996)

  17. 23.Cancer Chemotherapy: Resistance and Lipidic Metabolism. SGR (1996)

  18. 24.Cancer Chemotherapy: Resistance and Lipidic Metabolism. GRQ (1994)

  19. 25.Cloning of genes responsible for the gene amplification that develops upon cancer chemotherapy. CICYT-SAF (1994)

  20. 26.Molecular mechanism of action of deoxycoformycin in tumor cells. CNR (1993)

  21. 27.Regulation of the dhfr gene promoter throughout the cell cycle. Relationship with the gene amplification developed upon methotrexate treatment. FISss (1992)